Real-World Study on Use of Maixuekang Capsules Combined with Western Medicines in Treating Coronary Heart Disease

doi:10.19803/j.1672-8629.2021.08.01

Abstract

Abstract: Objective To analyze the combined use of Maixuekang capsules with western medicines in patients with coronary heart disease in the real world in order to provide data for the treatment of coronary heart disease with integrated traditional Chinese and western medicines. Methods The medical data on coronary heart disease inpatients who took Maixuekang capsules was retrieved from the information system database of 22 tertiary hospitals across the country from 2006 to 2016, and the association between Maixuekang capsules and western medicines was analyzed. Results Maixuekang capsules were most commonly used in combination with such western medicines as aspirin, isosorbide dinitrate, alprostadil, nifedipine and metoprolol in the treatment of coronary heart disease. The pharmacological types of western medicines were anticoagulants, vascular active drugs, calcium ion antagonists and antihypertensive drugs. Conclusion Maixuekang capsules are often used in combination with conventional western medicines in the treatment of coronary heart disease in the real world, and the medication regimens comply with clinical guidelines.

Key words: Maixuekang capsules, coronary heart disease, association rules, real world research

CLC Number:

R994.11

GENG Hongjiao, WANG Ya, ZHANG Yili, XIE Yanming, CHEN Renbo, GAI Guozhong, ZHANG Wenli. Real-World Study on Use of Maixuekang Capsules Combined with Western Medicines in Treating Coronary Heart Disease[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 701-704.

References

[1] Chen WW, Gao RL, Liu LS, et al.Summary of Chinese cardiov-ascular disease report 2016[J]. Chinese Journal of Circulation(中国循环杂志), 2017, 32(6): 521-530.
[2] Chen KT.Clinical study of Shuxinjiedu ointment for external treatment of coronary heart disease and angina pectoris[D]. Guang-zhou: Guangzhou University of Traditional Chinese Medicine, 2011.
[3] Gao S, Zhu Y.Systematic evaluation and meta analysis of the efficacy of integrated traditional Chinese and western medicine in the treatment of phlegm-turbid coronary heart disease[J]. World Journal of Integrated Traditional Chinese and Western Medicine(世界中西医结合杂志), 2018, 13(7): 909-913.
[4] Li SP, Li HX, Chen XL, et al.Effects of Maixuekang combined with cisplatin on the growth of subcutaneously transplanted tumors in nude mice bearing MHCC97H human liver cancer[J]. Chinese Journal of Traditional Chinese Medicine(中华中医药学刊), 2010, 28(9) : 1935-1937.
[5] Greinacher A, Warkentin TE.The direct thrombin inhibitor hirudin[J]. Thromb Haemost, 2008, 99(5) : 819-829.
[6] Mo W, Zhang YL, Chen HS, et al.A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition[J]. J Thromb Thrombolysis, 2009, 28(2) : 230-237.
[7] Ge CJ, Yuan CT, Sun ZY, et al.The effect of Maixuekang capsule combined with rosuvastatin on the severity of coronary artery disease in patients with borderline coronary disease[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine(中国中西医结合杂志), 2020, 40(1): 35-40 .
[8] Fuchs J, Cannon CP.Hirulog in the treatment of unstable angina: result of the thrombin inhibition in myocardial ischemia(TIMI) 7 trial[J]. Circulation, 1995, 92(4): 727.
[9] Zhuang Y, Xie BT, Weng SX, et al.Discussion on the design method of evaluating HIS "real world" integrated data warehouse after the market of traditional Chinese medicine[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2011, 36(20): 2880.
[10] Ge JB, Xu YJ, Wang C. Internal Medicine(内科学)[M]. 9th Ed. Beijing: People's Medical Publishing House, 2018: 218.
[11] World Health Organization.International Statistical Classification of Diseases and Related Health Problems (10th Revision)(国际疾病分类标准编码) [M]. 2th ed. Beijing: People's Medical Publishing House, 2008.
[12] Liu ML, Zhang XY, Ding L, et al.Application and progress of data mining methods in the study of the compatibility of traditional Chinese medicine[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2021, 32(2): 182-189.
[13] Liu L, Fu XJ, Li XB, et al.Bibliometrics analysis of cnki data mining of traditional chinese medicine[J]. World Science and Technology-Modernization of Traditional Chinese Medicine(世界科学技术-中医药现代化), 2020, 22(11): 3887-3893.
[14] Zhu MB.Introduction to Data Mining(数据挖掘导论)[M]. Hefei: University of Science and Technology of China Press, 2011: 102.
[15] Zhao L, Wang PK.Discovery of association rules: a review[J].Computer Engineering and Applications(计算机工程与应用), 2001, 37(8): 94-96.
[16] Wu XD, Zeng YZ.Data mining of college students' performance based on Apriori algorithm[J]. Journal of Langfang Teachers College (Natural Science Edition)(廊坊师范学院学报(自然科学版)), 2019, 19(1): 31-36.
[17] National Health and Family Planning Commission, Rational Drug Use Expert Committee, Chinese Pharmacists Association. Guidelines for rational use of drugs for coronary heart disease (Second Edition)[J].Frontier Journal of Chinese Medicine (Electronic Edition)(中国医学前沿杂志(电子版)), 2018, 10(6): 1-130.
[18] Zhou JL.Efficacy of maixuekang capsule in treating unstable angina pectoris of coronary heart disease[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine(深圳中西医结合杂志), 2019, 29(12): 59-60.
[19] Zhang ZZ.Research progress in modern pharmacology of leeches[J]. Digest of World Latest Medical Information(世界最新医学信息文摘), 2013, 17(13): 247.
[20] Li L, Yu X, Li Y, et al.Clinical study of Maixuekang capsules in the treatment of microvascular angina pectoris[J]. Clinical Journal of Chinese Medicine(中医临床研究), 2017, 9(24): 23-24.
[21] Rao HP.Efficacy of Maixuekang capsule in the treatment of middle-aged and elderly patients with coronary heart disease and angina pectoris[J]. Electronic Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular Diseases(中西医结合心血管病电子杂志), 2016, 4(30): 56-57.
[22] Ge CJ, Lu SZ, Liu H, et al.Effects of Maixuekang capsule on the platelet aggregation rate and long-term prognosis of patients with acute coronary syndrome treated by percutaneous coronary intervention[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine(中国中西医结合杂志), 2012, 32(7): 906-909.
[23] Lemesle G, de Labriolle A, Bonello L, et al. Incidence, predictors, and outcome of new, subsequent lesions treated with percutaneous coronary intervention in patients presenting with myocardial infarction[J]. Am J Cardial, 2009(103): 1189-1195.
[24] Gao LJ, Yang Q, Wang Z, et al.Effects of Maixuekang capsule on lipid metabolism and expression of adhesion molecules in hyperlipidemia rats[J]. Chinese Patent Medicine(中成药), 2013, 35(1): 1-5.
[25] Wang D.Effects of Maixuekang capsule combined with percuta-neous coronary intervention on platelet aggregation rate and high-sensitivity C-reactive protein in patients with acute coronary syndrome[J]. Journal of Practical Clinical Medicine(实用临床医药杂志), 2018, 22(5): 42-44.
[26] Luo CF.The effect of Maixuekang capsule combined with aspirin secondary prevention on carotid atherosclerosis in patients with myocardial infarction[J]. Clinical Medicine(临床医学), 2019, 39(7): 82-85.
[27] Chao TT, Zhang DW, Wang CL.Meta analysis of Maixuekang capsule combined with conventional western medicine in the treatment of unstable angina pectoris[J]. Chinese New Drugs and Clinical Pharmacology(中药新药与临床药理), 2021, 32(1): 128-134.